ERG and acute myeloid leukemia: ERG has been reported to be a megakaryocytic oncogene, and the fusion oncoprotein FUS-ERG targets key hematopoietic regulators and modulates the ATRA (all-trans retinoic acid) signaling pathway in t(16;21) AML (Kong et al., 1997; Salek-Ardakani et al., 2009; Sotoca et al., 2016).